What is the current Price Target for the Evaxion Biotech A/S - ADR stock?

The average Evaxion Biotech A/S - ADR target price is $31.92. This is 876.05% higher than the current stock price. The highest price target is 2,040.67%, the lowest is 83.49%. 3 Analysts have issued a price target Evaxion Biotech A/S - ADR 2026 .

How high will the Evaxion Biotech A/S - ADR stock rise?

No reliable answer can be given as to how high the Evaxion Biotech A/S - ADR stock will rise. The performance of stocks, including the Evaxion Biotech A/S - ADR stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Evaxion Biotech A/S - ADR stock today?

The performance of Evaxion Biotech A/S - ADR stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Evaxion Biotech A/S - ADR stock fall?

The decline in Evaxion Biotech A/S - ADR stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Evaxion Biotech A/S - ADR Forecast, price target & analysts

$3.19

2.45% today

Nasdaq, Feb 05, 07:20 pm CET

ISIN

US29970R1059

Symbol

EVAX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Evaxion Biotech A/S - ADR Target price 2025 - Analyst rating & recommendation

Evaxion Biotech A/S - ADR Classifications & Recommendation:

Buy

100%

Evaxion Biotech A/S - ADR Price Target

Target Price	$31.92
Price	$3.27
Potential	876.05% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Evaxion Biotech A/S - ADR 2026 . The average Evaxion Biotech A/S - ADR target price is $31.92. This is 876.05% register free of charge higher than the current stock price. The highest price target is $70.00 2,040.67% register free of charge , the lowest is $6.00 83.49% register free of charge .
	A rating was issued by 2 analysts: 2 Analysts recommend Evaxion Biotech A/S - ADR to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Evaxion Biotech A/S - ADR stock has an average upside potential 2026 of 876.05% register free of charge . Most analysts recommend the Evaxion Biotech A/S - ADR stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Revenue Million $	0.07	4.48
		6,300.43%

3 Analysts have issued a sales forecast Evaxion Biotech A/S - ADR 2024 . The average Evaxion Biotech A/S - ADR sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2023	$70.0k
2024	$4.5m 6,300.43% Unlock
2025	$7.9m 76.89% Unlock
2026	$19.9m 151.63% Unlock
2027	$67.8m 239.96% Unlock
2028	$48.1m 29.09% Unlock

Discover more stocks with a high price target

Uber Technologies 28.24%

BYD 28.04%

Porsche 27.62%

PayPal 24.21%

Tencent Holdings Ltd. 23.67%

Microsoft 23.34%

Alibaba Group Holding Ltd 19.22%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now